Summary
This 8-K filing from CVS Health Corp. (CVS) on September 5, 2019, primarily serves to announce the finalization of the regulatory approval process for its acquisition of Aetna. A final order was entered by the U.S. District Court for the District of Columbia, concluding the Tunney Act review and approving the proposed final judgment. This signifies the successful completion of the legal and regulatory hurdles associated with the significant Aetna acquisition. The approval, granted without conditions, marks the absolute end of any required judicial or governmental action regarding the Aetna deal. Investors can view this as a definitive step in integrating Aetna's operations into CVS Health, removing lingering uncertainty around the transaction's completion. The company had previously completed the divestiture of Aetna's individual standalone Medicare Part D prescription drug plans as a condition for the acquisition's approval.
Key Highlights
- 1Final court order issued by the U.S. District Court for the District of Columbia approving CVS Health's acquisition of Aetna.
- 2The order concludes the Tunney Act review, confirming the settlement with the U.S. Department of Justice is in the public interest.
- 3The court's approval was granted without any conditions.
- 4This filing signifies the final step in the regulatory approval process for the Aetna acquisition.
- 5No further action is required by the District Court, DOJ, or any other entity regarding the acquisition.
- 6Aetna's sale of its standalone Medicare Part D prescription drug plans, a condition for the acquisition, was completed on November 30, 2018.